Relay Therapeutics (RLAY) Price & Analysis

Compare

534 Followers

RLAY Stock Chart & Stats

$6.76

>-$0.01(-0.22%)

At close: Jan 08 4:00 PM EST

$6.76

>-$0.01(-0.22%)

Day’s Range― - ―

52-Week Range$1.78 - $7.19

Previous CloseN/A

Volume391.09K

Average Volume (3M)1.63M

Market Cap

$1.18B

Enterprise Value-$30.02M

Total Cash (Recent Filing)$113.94M

Total Debt (Recent Filing)$34.18M

Price to Earnings (P/E)―

Beta2.07

Next Earnings

Feb 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding172,411,400

10 Day Avg. Volume1,765,130

30 Day Avg. Volume1,633,133

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.03

Enterprise Value/Revenue-3.59

Enterprise Value/Gross Profit23.88

Enterprise Value/Ebitda0.09

Forecast

1Y Price Target

$13.71

Price Target Upside102.81% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressThe ongoing, fully-funded phase 3 breast cancer trial for RLY-2608 shows promising results, with its phase 1b progression-free survival doubling the expected control performance.

Competitive AdvantageRLAY leads all competitors of its mutant-selective class by 18-24 months, suggesting a significant competitive advantage.

Financial StabilityRelay Therapeutics ended the quarter with $656.8M in cash, providing an operational runway into 2029.

Bears Say

Development RisksRisks include negative clinical data, slower than expected development timelines, and setbacks in later-stage trials.

Relay Therapeutics News

Relay Therapeutics reports Q3 EPS (43c), consensus (42c)

“We are pleased with the clinical progress we’ve made across all three of our RLY-2608 trials in breast...

1h ago

RLAY

Relay Therapeutics Expands Board with New Appointments

Relay Therapeutics ( ($RLAY) ) just unveiled an announcement. On November 4, 2025, Relay Therapeutics expanded its Board...

2h ago

RLAY

Relay Therapeutics’ Promising Phase 2 Study on RLY-2608: A Potential Game-Changer in Targeted Therapy

Relay Therapeutics Inc (($RLAY)) announced an update on their ongoing clinical study. Relay Therapeutics Inc. is conducting a...

2M ago

RLAY

Guggenheim assumes Relay with Buy, names best idea

Guggenheim analyst Brad Canino assumed coverage of Relay Therapeutics (RLAY) with a Buy rating and price target of...

2M ago

RLAY

Relay Therapeutics assumed with a Buy at Guggenheim

Guggenheim assumed coverage of Relay Therapeutics (RLAY) with a Buy rating and price target of $15, up from...

2M ago

RLAY

Relay Therapeutics price target lowered to $14 from $16 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Relay Therapeutics (RLAY) to $14 from $16...

2M ago

RLAY

Relay Therapeutics price target lowered to $19 from $29 at Raymond James

Raymond James lowered the firm’s price target on Relay Therapeutics (RLAY) to $19 from $29 and keeps a...

3M ago

RLAY

Relay Therapeutics Reports Q2 2025 Financial Results and Progress

Relay Therapeutics Inc ( ($RLAY) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

RLAY

Relay Therapeutics reports Q2 EPS (41c), consensus (47c)

Reports Q2 revenue $677,000, consensus $75,000. “It is an exciting time for Relay as we have initiated our...

3M ago

RLAY

Relay Therapeutics’ Phase 3 Study: A New Hope for Advanced Breast Cancer Treatment

Relay Therapeutics Inc (($RLAY)) announced an update on their ongoing clinical study. Relay Therapeutics Inc. is conducting a...

3M ago

RLAY

Relay Therapeutics has positive read from Celcuity data, says Barclays

After Celcuity (CELC) announced topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial evaluating...

3M ago

CELC

RLAY

Claire Mazumdar Joins Relay Therapeutics as Director

Relay Therapeutics ( ($RLAY) ) just unveiled an announcement. On June 8, 2025, Jami Ruben resigned from the...

5M ago

RLAY

Relay Therapeutics Holds 2025 Annual Stockholder Meeting

Relay Therapeutics ( ($RLAY) ) has shared an update. On June 6, 2025, Relay Therapeutics held its 2025...

5M ago

RLAY

Relay Therapeutics Announces Lease Termination Agreement

An announcement from Relay Therapeutics ( ($RLAY) ) is now available. On June 3, 2025, Relay Therapeutics, Inc....

5M ago

RLAY

RLAY FAQ

What was Relay Therapeutics’s price range in the past 12 months?

Relay Therapeutics lowest stock price was $1.77 and its highest was $7.19 in the past 12 months.

What is Relay Therapeutics’s market cap?

Relay Therapeutics’s market cap is $1.18B.

When is Relay Therapeutics’s upcoming earnings report date?

Relay Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 105 days.

How were Relay Therapeutics’s earnings last quarter?

Relay Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.415 by -$0.015.

Is Relay Therapeutics overvalued?

According to Wall Street analysts Relay Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Relay Therapeutics pay dividends?

Relay Therapeutics does not currently pay dividends.

What is Relay Therapeutics’s EPS estimate?

Relay Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Relay Therapeutics have?

Relay Therapeutics has 172,411,400 shares outstanding.

What happened to Relay Therapeutics’s price movement after its last earnings report?

Relay Therapeutics reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.415. Following the earnings report the stock price went down -7.736%.

Which hedge fund is a major shareholder of Relay Therapeutics?

Currently, no hedge funds are holding shares in RLAY

Relay Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-46.24%

Trailing 12-Months

Asset Growth

-5.66%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Relay Therapeutics

Relay Therapeutics is a biotechnology company that focuses on transforming the drug discovery process through its proprietary Dynamo platform, which leverages cutting-edge computational techniques and biophysics to design targeted therapies. The company primarily operates in the field of precision medicine, aiming to treat diseases such as cancer by developing novel small molecule drugs that specifically target protein motions and dynamics. Relay Therapeutics is dedicated to advancing its pipeline of drug candidates through various stages of clinical development, focusing on high-impact therapeutic areas.

Relay Therapeutics (RLAY) Earnings & Revenues

Historic Earnings Reports

RLAY Stock 12 Month Forecast

Average Price Target

$13.71

▲(102.81% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","20":"$20","5.75":"$5.75","10.5":"$10.5","15.25":"$15.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,5.75,10.5,15.25,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.32,6.372307692307693,7.424615384615385,8.476923076923077,9.52923076923077,10.581538461538463,11.633846153846154,12.686153846153847,13.73846153846154,14.790769230769232,15.843076923076925,16.895384615384614,17.947692307692307,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.32,5.9653846153846155,6.610769230769231,7.256153846153847,7.901538461538462,8.546923076923077,9.192307692307693,9.837692307692308,10.483076923076924,11.12846153846154,11.773846153846154,12.41923076923077,13.064615384615387,{"y":13.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.32,5.218461538461539,5.116923076923078,5.015384615384615,4.913846153846154,4.812307692307693,4.710769230769231,4.609230769230769,4.507692307692308,4.406153846153846,4.304615384615385,4.203076923076923,4.101538461538461,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.55,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.84,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.67,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.47,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.41,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.18,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.36,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.32,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >